Cancer vaccines are a form of immunotherapy that can generate antigen-specific antitumor immunity to achieve long-term cancer elimination. Conventional cancer vaccines typically require multiple administrations to generate enduring anti-tumor immune responses. Additionally, administering the therapy as a bolus can diminish vaccine efficacy by accelerating its diffusion throughout the body. To address these challenges, we developed the “NanoLymph”, a subcutaneous implantable platform for targeted cancer immune modulation. This is a transcutaneously accessible dual-reservoir system capable of sustained release of immunoadjuvants from a drug reservoir into a cell reservoir through a nanoporous membrane. The Nanolymph promotes in situ immune cell recruitment, homing and activation through an antigen-loaded collagen scaffold embedded within the cell reservoir.